EGFR+ Lung Cancer | Clinical

Osimertinib Plus Bevacizumab Does Not Improve PFS in EGFR-Mutated NSCLC

September 18, 2021

Osimertinib (Tagrisso) plus bevacizumab does not produce a superior progression-free survival (PFS) benefit over osimertinib monotherapy in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation. However, for patients who have a history of smoking or an exon 20 deletion, the combination may prove beneficial.